Ascendis Health Limited (JSE:ASC)
South Africa
· Delayed Price · Currency is ZAR · Price in ZAc 80.00
-6.00 (-6.98%)
Apr 17, 2025, 2:54 PM SAST
Ascendis Health Revenue
Ascendis Health had revenue of 734.49M ZAR in the twelve months ending December 31, 2024, down -50.90% year-over-year. In the fiscal year ending June 30, 2024, Ascendis Health had annual revenue of 1.47B, down -4.13%.
Revenue (ttm)
734.49M
Revenue Growth
-50.90%
P/S Ratio
0.68
Revenue / Employee
52.46M
Employees
14
Market Cap
500.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 1.47B | -63.39M | -4.13% |
| Jun 30, 2023 | 1.54B | -24.02M | -1.54% |
| Jun 30, 2022 | 1.56B | -266.01M | -14.57% |
| Jun 30, 2021 | 1.83B | -377.56M | -17.14% |
| Jun 30, 2020 | 2.20B | -3.67B | -62.48% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clicks Group | 46.80B |
| Aspen Pharmacare Holdings | 45.53B |
| Dis-Chem Pharmacies | 37.99B |
| Life Healthcare Group Holdings | 25.79B |
| Netcare | 25.20B |
| Adcock Ingram Holdings | 9.62B |
| AfroCentric Investment Corporation | 8.81B |
| RH Bophelo | 280.76M |
Ascendis Health News
- 18 days ago - Ascendis submits NDA for TransCon CNP for achondroplasia - Seeking Alpha
- 5 months ago - Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate - Seeking Alpha
- 7 months ago - Ascendis Challenges BioMarin, But Market Response Seems Excessive - Seeking Alpha
- 7 months ago - Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term - Benzinga
- 7 months ago - BioMarin off 17% as Ascendis data seen as threat to Voxzogo - Seeking Alpha
- 7 months ago - Ascendis gets FDA orphan drug status for Yorvipath for hypothyroidism - Seeking Alpha
- 8 months ago - Ascendis raised to outperform by Oppenheimer ahead of drug launch - Seeking Alpha
- 8 months ago - Ascendis stock falls 12% amid lowered outlook, royalty deal - Seeking Alpha